288 related articles for article (PubMed ID: 17644711)
1. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
3. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
[TBL] [Abstract][Full Text] [Related]
4. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
[TBL] [Abstract][Full Text] [Related]
5. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
8. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
9. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
11. Treatment of isoniazid-resistant pulmonary tuberculosis.
Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Lim SY; Lim SY; Koh WJ
BMC Infect Dis; 2008 Jan; 8():6. PubMed ID: 18211720
[TBL] [Abstract][Full Text] [Related]
12. [Bactericidal therapy in patients with tuberculosis].
Krasnov VA; Ursov IG
Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
[No Abstract] [Full Text] [Related]
13. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
[TBL] [Abstract][Full Text] [Related]
14. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
[TBL] [Abstract][Full Text] [Related]
16. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant tuberculosis in Budapest.
Fodor T; Vadász I; Lõrinczi I
Int J Tuberc Lung Dis; 1998 Sep; 2(9):732-5. PubMed ID: 9755927
[TBL] [Abstract][Full Text] [Related]
18. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
19. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
20. Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.
Gokarn K; Pal RB
BMC Complement Altern Med; 2017 Mar; 17(1):161. PubMed ID: 28327117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
